Physician profile
Mark M Kim
NPI 1578597282
$1,368.45
in general payments reported to CMS, 2019-2025
19 companies · $62.29 in 2025
The $62.29 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $91.12 · 2022: $21.87 · 2025: $62.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $231.65 | 2019-2020 | |
| Novo Nordisk INC | $221.02 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $210.46 | 2019-2022 | |
| Lilly USA, LLC | $173.75 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.54 | 2019 | |
| Amgen INC. | $55.66 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.20 | 2019 | |
| Amarin Pharma, INC. | $44.91 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $40.65 | 2019-2020 | |
| Ucb, INC. | $22.17 | 2019 | |
| Dynavax Technologies Corporation | $19.79 | 2019 | |
| Abbvie INC. | $15.13 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.82 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $13.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.